Rifaximin + Lactulose
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hepatic Encephalopathy
Conditions
Hepatic Encephalopathy, Cirrhosis
Trial Timeline
Jan 8, 2013 → Dec 17, 2014
NCT ID
NCT01842581About Rifaximin + Lactulose
Rifaximin + Lactulose is a approved stage product being developed by Bausch Health for Hepatic Encephalopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01842581. Target conditions include Hepatic Encephalopathy, Cirrhosis.
What happened to similar drugs?
2 of 17 similar drugs in Hepatic Encephalopathy were approved
Approved (2) Terminated (5) Active (12)
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01842581 | Approved | Completed |
| NCT00364689 | Phase 3 | Terminated |
Competing Products
20 competing products in Hepatic Encephalopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ITF2357 | Biotrial | Phase 1 | 19 |
| GB1211 + Placebo | Comac Medical | Phase 1/2 | 18 |
| ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results) | Idorsia | Phase 1 | 23 |
| Olomorasib | Eli Lilly | Phase 1 | 29 |
| Simufilam | Cassava Sciences | Phase 1 | 19 |
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 40 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 35 |
| DS-3201b | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 36 |
| Pexidartinib | Daiichi Sankyo | Phase 1 | 29 |
| Tivantinib + Tivantinib + Tivantinib + Tivantinib | Daiichi Sankyo | Phase 1 | 29 |
| Bocidelpar | Astellas Pharma | Phase 1 | 29 |
| fezolinetant | Astellas Pharma | Phase 1 | 29 |
| enzalutamide | Astellas Pharma | Phase 1 | 29 |
| ASP015K | Astellas Pharma | Phase 1 | 29 |
| ASP2215 | Astellas Pharma | Phase 1 | 29 |
| BPN14770 | Shionogi | Phase 1 | 29 |
| S-217622 | Shionogi | Phase 1 | 29 |
| Lemborexant | Eisai | Phase 1 | 29 |